Olmesartan Medoxomil Zentiva (Olmesartan Medoxomil)

Olmesartan is an angiotensin II receptor blocker used to manage high‑blood‑pressure related conditions.

• Essential hypertension: lowers systolic and diastolic blood pressure, helping achieve target values.
• Hypertension with type 2 diabetes: reduces cardiovascular risk by controlling blood pressure in diabetic patients.
• Left ventricular hypertrophy secondary to hypertension: slows progression of cardiac remodeling.

• Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth muscle and adrenal gland cells. This inhibition prevents vasoconstriction and aldosterone secretion, leading to relaxation of blood vessels, reduced peripheral resistance, and a decrease in blood pressure. The drug does not affect bradykinin metabolism, which differentiates it from ACE inhibitors.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain often occurring during the first weeks of therapy.
• Fatigue: general tiredness without a clear cause.
• Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue or throat that may compromise breathing.
• Hyperkalemia: elevated potassium levels that can affect heart rhythm.
• Acute renal failure: sudden decline in kidney function, indicated by reduced urine output or increased serum creatinine.

Before initiating therapy, consider the following precautions:

• Monitor blood pressure: ensure adequate control and avoid excessive hypotension.
• Assess renal function: check serum creatinine and eGFR periodically.
• Check serum potassium: especially when combined with potassium‑sparing agents.
• Avoid in pregnancy: teratogenic risk; discontinue if pregnancy is confirmed.
• Use caution in elderly patients: start at lower doses and monitor for orthostatic effects.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan may interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined use can increase risk of renal impairment.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• ACE inhibitors: concurrent use raises the likelihood of angioedema.
• NSAIDs: can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: additive blood‑pressure‑lowering effect, monitor for hypotension.
• Lithium: olmesartan may increase lithium concentrations; monitor serum levels.
• Cyclosporine: may elevate serum creatinine; regular renal monitoring is advised.